In AD APP/PS1 mice, metformin (200 mg/kg i.p.; 14 days) reduced Aβ levels and inflammatory responses (IL-1β and TNF-α), improving spatial memory and neurogenesis of the hippocampus. Here, IL1B is linked to Alzheimer disease.